Pressmeddelande -

PledPharma reports positive results from cancer study

Accelerator’s subsidiary PledPharma has, in collaboration with the Oncology Clinic at Ryhov County Hospital in Jönköping, conducted a small randomized clinical trial on patients who have had surgery for colorectal cancer and then received chemotherapy.

 

No serious side effects of the chemotherapy were observed in the patients who received PP-095 (mangafodipir), while several serious side effects (grades 3 and 4 on the 4-point NCI-CTCAE scale) were observed in the patients who received placebo. The difference between the groups is statistically significant.

 

”Today, serious side effects of chemotherapy treatment are a major problem for patients with colorectal cancer”, says Professor Ursula Falkmer who is in charge of the study. She also says that we now have effective antineoplastic agents for use in the treatment of colorectal cancer but points out that their side effects render their use more difficult. It is therefore desirable that forms of treatment are found that can reduce the side effects and thereby render the chemotherapy more effective.

 

”This is the first time that we test on patients to establish whether mangafodipir reduces the side effects. Consequently, the study comprises relatively few patients, however the results are unquestionably interesting” Professor Falkmer continues. ”We therefore look forward with great anticipation to continuing with the clinical trials”.

The study was designed to establish whether pre-treatment with the PLED-derivative PP-095 reduces serious FOLFOX6-induced adverse events during adjuvant chemotherapy according to the FOLFOX6 regimen in patients operated for colorectal cancer stage Dukes’ C. Fourteen patients were randomized to receive either pre-treatment with placebo or mangafodipir during 3 FOLFOX6 cycles.

 

For further information, please contact Andreas Bunge CEO at  +46 70 824 25 25

 

Ämnen

  • Ekonomi, finans

Kategorier

  • accelerator
  • pledpharma
  • chemotherapy
  • colorectal cancer

Regioner

  • Stockholm

Accelerator Nordic AB is a group of development companies in the field of Scandinavian Life Science. The company holds an active majority position in a number of companies providing Pharmaceutical and Medical technology products. The Accelerator Group addresses therapeutics and imaging in large growth markets such as oncology, cardiology and drug delivery for orthopedic and dental implants. The company has products in clinical phase II and in the initial commercialization phase. The business model is centred on partnering or out-licensing. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm, Sweden. For more information, please visit, www.acceleratorab.se

 

PledPharma AB develops new pharmaceutical applications based on a clinically approved PLED-derivative with an initial candidate for oncology. PledPharma’s core technology is an omnipotent low molecular weight enzyme mimetic (lowMEM) with SOD mimetic activity that has characteristics to protect healthy cells during cancer treatment with chemotherapy and/or radiation. When used as an adjunct treatment, it has the potential to improve both clinical outcomes and patient well-being. In addition to cancer treatment, SOD mimetics have a wide range of potential indications, e.g., myocardial infarction, stroke and neurodegenerative diseases. For more information, please visit www.pledpharma.se

Kontakter

Relaterad media

Relaterat innehåll

  • PledPharma rapporterar positiva resultat från cancerstudie

    Inga allvarliga biverkningar av cellgiftsbehandlingen sågs hos de patienter som fick PP-095 (mangafodipir), medan flera allvarliga biverkningar (grad 3 och 4 på den 4-gradiga s.k. NCI-CTCAE skalan) sågs hos de patienter som fick placebo.

  • SyntheticMR sells first software to Bern

    Accelerators subsidiary SyntheticMR has together with distributor Sectra secured the first order for the software SyMRI Suite from the Institute of Forensic Medicine at the University of Bern. The software will enhance quality in conjunction with virtual autopsies.

  • Accelerator ökar innehavet i PledPharma

    Accelerator ökar till 68,86 % ägande i PledPharma AB genom att i en nyemission tillföra dotterbolaget 5 mkr. Investeringen ska underlätta för PledPharma att utvecklas till ett självständigt bolag.

Fyll i din epostadress för att följa Accelerator Nordic AB

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Accelerator Nordic AB.

Okej